Status: Recruiting
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Alexander B Olawaiye, MDUpdated: Jun 18, 2026Locations: 1
Eligibility criteria
Females age ≥ 18 years (at time of signing informed consent) [+20]
Current or anticipated use of medications known to be strong inhibitors or induc... [+22]